Cargando...
BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2
PURPOSE: Neuroendocrine prostate cancer (NEPC), an aggressive variant of CRPC, often emerges after AR-targeted therapies such as enzalutamide (ENZ) or de novo, via trans-differentiation process of neuroendocrine differentiation. The mechanistic basis of NED is poorly understood, contributing to lack...
Guardado en:
| Publicado en: | Clin Cancer Res |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6825556/ https://ncbi.nlm.nih.gov/pubmed/31371344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0498 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|